Frederik Persson

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Hans‐Henrik Parving, Barry M. Brenner, John J.V. McMurray et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

Hans‐Henrik Parving, Frederik Persson, Julia B. Lewis et al. · New England Journal of Medicine · 2008 · 1.1K citations · Full text

Medicine, Internal Medicine, Nephrology +11

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Kåre I. Birkeland, Marit E. Jørgensen, Bendix Carstensen et al. · The Lancet Diabetes & Endocrinology · 2017 · 371 citations

Medicine, Internal Medicine, Pharmacotherapy +17

Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy

Petra Zürbig, George Jerums, Peter Hovind et al. · Diabetes · 2012 · 269 citations · Full text

Medicine, Biochemistry, Nephrology +17

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial

Nete Tofte, Morten Lindhardt, Katarina Adamova et al. · The Lancet Diabetes & Endocrinology · 2020 · 254 citations · Full text

Medicine, Endocrinology, Nephrology +17